Who should Allergan buy next? We asked, you answered

Serial buyer Allergan ($AGN) is getting ready to head back to the bargaining table, and there's plenty of buzz about who its next target will be. Who should it be, though, as far as FiercePharma readers are concerned?

That's the question we posed last Tuesday, and since then, more than 500 of you have weighed in. No, it's not Biogen ($BIIB) or Pfizer ($PFE), the two favorites in Evercore ISI analyst Umer Raffat's recent poll.

Instead, readers chose AbbVie ($ABBV), which last year inked--and later dumped--a $55 billion pact for Ireland's Shire ($SHPG) in an attempt to diversify beyond lead med and biosimilar target Humira.

Speaking of Shire, though, readers favored the Irish pharma as an Allergan deal partner, too. It snagged 13% of the vote, compared with AbbVie's 17.2%--and Biogen, Amgen ($AMGN) and Pfizer each garnered more than 10%, too.

Take a look at full results below; in addition to the options we posed, readers suggested companies like Jazz ($JAZZ), Concordia and even Novartis ($NVS) as ones for Allergan to watch. 

Now, it's up to the Dublin drugmaker to do its thing. And, as always, we'll keep you posted when it makes its move.

Thanks for voting! Carly Helfand (email | Twitter)

 

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.